Table 1 Demographic and clinical characteristics of the patients
N | All patients | Exacerbations previous year | p | ||
|---|---|---|---|---|---|
0 | 1 | ≥2 | |||
72 | 31 | 18 | 23 | ||
Age, mean (SD) | 68 (7.9) | 66 (9) | 69 (7) | 68 (7) | 0.387 |
Sex (male), n (%) | 64 (88.9) | 27 (87.1) | 16 (88.9) | 21 (91.3) | 0.888 |
Cumulative smoking (pack-year), median (IQR) | 60 (45–80) | 60 (44–76) | 50 (41–85) | 60 (49–97) | 0.383 |
Postbronchodilator FEV1%, median (IQR) | 44 (33–60) | 52 (42–70) | 35 (32–52) | 35 (28–49) | 0.001 |
BMI, median (IQR) | 27 (24–30) | 28 (25–29) | 28 (23–30) | 26 (23–30) | 0.669 |
Blood eosinophils (× 109/L), median (IQR) | 200 (100–270) | 200 (130–3009 | 185 (92–255) | 200 (100–300) | 0.414 |
Blood eosinophils (%), median (IQR) | 2.4 (1.4–3.4) | 2.8 (1.7–3.6) | 2 (1.3–2.8) | 1.8 (1.1–3.4) | 0.156 |
Blood leucocytes (×109/L), median (IQR) | 7845 (6635–9180) | 7210 (6520–8940) | 7915 (6505–8510) | 8110 (7030–10,170) | 0.481 |
Exacerbations last year, median (IQR) | 1 (0–2) | 0 | 1 | 3 (2–4) | |
Airflow limitation severity (GOLD), n (%) | |||||
GOLD 1 | 6 (8.3) | 5 (16.1) | 0 (0) | 1 (4.3) | 0.013 |
GOLD 2 | 19 (26.4) | 11 (35.5) | 4 (22.2) | 4 (17.4) | |
GOLD 3 | 36 (50) | 14 (45.2) | 12 (66.7) | 10 (11.1) | |
GOLD 4 | 11 (15.3) | 1 (3.2) | 2 (18.2) | 8 (34.8) | |